Results 1 to 10 of about 21,990 (200)

Delivery and Biosafety of Oncolytic Virotherapy [PDF]

open access: yesFrontiers in Oncology, 2020
In recent years, oncolytic virotherapy has emerged as a promising anticancer therapy. Oncolytic viruses destroy cancer cells, without damaging normal tissues, through virus self-replication and antitumor immunity responses, showing great potential for ...
Bin Tang
exaly   +5 more sources

Strategies for Advanced Oncolytic Virotherapy: Current Technology Innovations and Clinical Approaches

open access: yesPharmaceutics, 2022
Oncolytic virotherapy is a type of nanomedicine with a dual antitumor mechanism. Viruses are engineered to selectively infect and lyse cancer cells directly, leading to the release of soluble antigens which induce systemic antitumor immunity ...
Andreas E. Albers, Meiyu Fang, Xu Qian
exaly   +4 more sources

Syncytia Formation in Oncolytic Virotherapy [PDF]

open access: yesMolecular Therapy - Oncolytics, 2019
Oncolytic virotherapy uses replication-competent virus as a means of treating cancer. Whereas this field has shown great promise as a viable treatment method, the limited spread of these viruses throughout the tumor microenvironment remains a major ...
Eric Bartee
exaly   +5 more sources

Oncolytic Virotherapy for Melanoma Brain Metastases, a Potential New Treatment Paradigm?

open access: yesBrain Sciences, 2021
Introduction: Melanoma brain metastases remain a devastating disease process with poor prognosis. Recently, there has been a surge in studies demonstrating the efficacy of oncolytic virotherapy for brain tumor treatment.
Turki Elarjani   +2 more
exaly   +4 more sources

Recent advances in oncolytic virotherapy: insights from clinical trials and combination treatment strategies [PDF]

open access: yesVirology Journal
Background and aim Oncolytic virotherapy is a novel therapeutic paradigm in oncology that uses viruses to selectively replicate within cancer cells, causing targeted tumor cell destruction with minimal toxicity to healthy tissues.
Omid Salahi Ardekani   +5 more
doaj   +2 more sources

Vesicular Stomatitis Virus-Based Oncolytic Virotherapy: Recent Progress and Emerging Trends [PDF]

open access: yesCurrent Oncology
Oncolytic virotherapy has emerged as a promising and innovative approach to cancer treatment, leveraging viruses that selectively replicate in tumor cells and cause their destruction (oncolysis), while simultaneously stimulating anti-tumor immune ...
Cassandra Catacalos-Goad   +2 more
doaj   +2 more sources

Experimental models for developing oncolytic virotherapy for metastatic prostate cancer [PDF]

open access: yesFrontiers in Immunology
Cancer has remained the second leading cause of death worldwide for over a century. Despite significant advances, effectively targeting cancer cells and overcoming therapeutic challenges remain critical goals.
Ying-Cheng Chen, Marxa Leão Figueiredo
doaj   +2 more sources

Lung cancer and oncolytic virotherapy——enemy's enemy

open access: yesTranslational Oncology, 2023
Lung cancer is one of the malignant tumors that seriously threaten human health worldwide, while the covid-19 virus has become people's nightmare after the coronavirus pandemic. There are too many similarities between cancer cells and viruses, one of the
Zhang Li   +3 more
doaj   +1 more source

Current strategies in engaging oncolytic viruses with antitumor immunity

open access: yesMolecular Therapy: Oncolytics, 2021
Oncolytic virotherapy has produced promising yet limited results in preclinical and clinical studies. Besides direct oncolytic activity, a significant therapeutic mechanism of oncolytic virotherapy is the induction of tumor-specific immunity ...
Drew Ashton Boagni   +2 more
doaj   +1 more source

Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies

open access: yesJournal of Hematology & Oncology, 2021
Bispecific T cell engagers (BiTEs) are an innovative class of immunotherapeutics that redirect T cells to tumor surface antigens. While efficacious against certain hematological malignancies, limited bioavailability and severe toxicities have so far ...
Johannes P. W. Heidbuechel   +1 more
doaj   +1 more source

Home - About - Disclaimer - Privacy